Navigation Links
Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer
Date:1/6/2014

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Ajinomoto Althea Inc., a leading Contract Manufacturing Organization providing development and manufacturing services for biotechnology and pharmaceutical companies, announced today the appointment of J. David Enloe Jr. as President and CEO. Mr. Enloe will be responsible for developing strategies to support the company's continued growth.

(Logo: http://photos.prnewswire.com/prnh/20131104/LA10040LOGO)

"We are delighted to welcome David as the new leader of Ajinomoto Althea's management team," said Dr. Hiroshi Shiragami, Co-Chair of Ajinomoto Althea Inc. "His unique depth of experience in the biotechnology industry, leadership abilities, financial management, manufacturing and contractual negotiation skills will be instrumental in supporting further expansion of our business."  

Mr. Enloe brings over 20 years of executive management experience most of that in biotechnology, drug development, and GMP manufacturing management.  Most recently, he served as the Head of the Viral Therapeutics Business Unit at Lonza AG, which provides process development, scale-up and GMP manufacturing of viral-based biologics for clients in the US, Europe and Asia.  David was the founder and CEO of Vivante GMP Solutions, Inc., which he subsequently sold to Lonza AG in 2010. Prior to this, he was President and CEO of Introgen Therapeutics, Inc., which later became the basis for Vivante.

"I can't think of a better fit for Ajinomoto Althea.  David's leadership and experience combined with the Ajinomoto Althea team will enhance the company's position as the most trusted outsource manufacturer for those developing tomorrow's successful therapeutics," stated Dr. Magda Marquet, Co-Chair of Ajinomoto Althea Inc.

"I am thrilled to be joining Ajinomoto Althea Inc. at this exciting stage in its history.  Althea has been an outstanding organization for many years now, and with the recent acquisition by Ajinomoto, the company is positioned to expand and grow into an even more significant player in the biologics production and fill/finish markets. The timing of this opportunity for me was perfect and I can't wait to get started," said Mr. Enloe.

Mr. Enloe joined the team effective December 16, 2013.  Dr. Hiroshi Shiragami and Dr. Magda Marquet will continue to serve Ajinomoto Althea Inc. as Co-Chairs of the Board of Directors.

About Ajinomoto Althea  Inc.

Ajinomoto Althea, Inc. is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services.  Ajinomoto Althea offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Ajinomoto Althea offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Ajinomoto Althea's formulation technology platform includes Crystalomics®, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. Ajinomoto Althea also has an innovative and proven recombinant protein expression technology called Corynex®. For more information visit us at WWW.ALTHEATECH.COM.


'/>"/>
SOURCE Ajinomoto Althea Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shanghai Ajinomoto Amino Acid Co., Ltd. Expands Amino Acid Production Capacity
2. Ajinomoto Althea, Inc. Selected As A Finalist In 26TH Annual CONNECT Most Innovative New Product Awards
3. Ajinomoto Co., Inc. Completes Acquisition of Althea Technologies, Inc.
4. Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.
5. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
6. Concord Medical Announces Results of 2013 Annual General Meeting; Appoints New Board Members
7. ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors
8. BioMed Realty Trust Appoints Dr. William R. Brody, President Of The Salk Institute, To Its Board Of Directors
9. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
10. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
11. Hologic Appoints Stephen P. MacMillan President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... , July 13, 2017  New York City-based market research ... markets should be aware of.  From new products to new ... detailed in a recently completed study, Potential Pipeline Disruptors ... 1.  Age-Driven Growth - True ... been aware of the impact the growing population and, to ...
(Date:7/12/2017)...  Eli Lilly and Company (NYSE: LLY ) ... resolve pending patent litigation in the U.S. District Court for ... the Cialis ® (tadalafil) unit dose patent. This patent ... part of the agreement, Cialis exclusivity is now expected to ... "The unit dose patent for Cialis is valid and infringed ...
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider of ... with WALLIX to expand its solution to help government contractors more quickly ... number of ways to address the authentication requirements within NIST SP800-171, but no ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... fat (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 ... its adipose filtration technology. The '398 and '324 patents cover methods and ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating clubfoot as ... 100,000 children in their treatment program. Clubfoot is a pervasive problem in the ... is limited or non-existent. Without intervention, these children are destined to grow up ...
(Date:7/24/2017)... ... 24, 2017 , ... On July 19th, the Chinese Academy ... the awarding ceremony was held successfully in Beijing. The State Health Planning Commission, ... system, and national Chinese medicine experts also attended the event, including more than ...
Breaking Medicine News(10 mins):